Company overview
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201 and HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer. The company has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing HCWB with another company.
| Daily close (USD) | $1.53 |
| Market capitalization (USD) | $2,809,575.72 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.38 |
No matching rows. Clear the filter to see all records.
Read HCWB's valuation metrics
Company size
HCW Biologics Inc. Common Stock's recorded market capitalization is $2,809,575.72. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
HCWB's recorded price-to-book ratio is 0.38. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research HCW Biologics Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about HCWB. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow HCWB's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.